Drug Trial Radar · NCT06920901
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Mar 27, 2025
Primary completion
Sep 17, 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Apogee Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Conditions
- Asthma
Interventions
APG777Drug
APG777 subcutaneous injection
PlaceboDrug
Matching placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 52 weeks
- Number of Participants with Abnormal Laboratory FindingsTime frame: Up to 52 weeks
- Number of Participants with Abnormal Vital SignsTime frame: Up to 52 weeks
- Number of Participants with Abnormal Electrocardiograms (ECGs)Time frame: Up to 52 weeks
- Number of Participants with Abnormal Physical Examination FindingsTime frame: Up to 52 weeks
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site
La Jolla, California
Investigational Site
Long Beach, California
Investigational Site
San Jose, California
Investigational Site
Torrance, California
Investigational Site
Normal, Illinois
Investigational Site
Kansas City, Missouri
Investigational Site
Edmond, Oklahoma
Investigational Site
Philadelphia, Pennsylvania
Investigational Site
Pittsburgh, Pennsylvania
Investigational Site
Manchester, United Kingdom
Investigational Site
Bradford, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.